Table 1. Studies of single-agent therapies identified in our targeted literature review and the reported data on ORR, CRR, and DRR.
| Regimen | Patients, n | Median age, years (range) | Study design | Median number of prior therapies | ORR (%) | CR (%) | Reported DRR (%) |
|---|---|---|---|---|---|---|---|
| Rituximab [18] | 54 | 62.5 (20–83) Group A 65 (32–86) Group B |
Phase II, open-label, randomized | NR | 31 | 9 | - |
| Gemcitabine [20] | 30 | 61 | Phase II | 2 | 20 | 0 | - |
| Bendamustine [22] | 18 | 66 (38–84) | Phase II | 2 | 44 | 17 | - |
| Oxaliplatin [21] | 22a | 62 (28–79)b | Phase II | 2b | 32a | 9a | - |
| Vorinostat [17] | 18 | 66.5 (59–86) | Phase II | 2 | 6 | 6 | 6 |
| Pixantrone [16] | 70c | 60 (18–80) | Phase III, open-label, randomized | 3 | 37 | 20 | 17 |
| Ibrutinib [24] | 80 | 60 (34–89) ABC 65 (28–92) GCB 63 (44–85) Unclassified 65 (58–78) Unknown |
Phase I/II | 3d 3.5f | 25e | 10 | - |
| Lenalidomide [19] (for DRR estimation) | 51g | 69 (28–84) | Phase II/III, open-label, randomized | 2 | 28 | 10 | - |
| Lenalidomide [23] (for CRR estimation) | 49 (n = 26 for DLBCL only) | 65 (23–86) | Phase II | 4 | 35 (19 for DLBCL) | 12 (12 for DLBCL) | - |
| Lenalidomide [25] (for CRR estimation) | 217 (n = 108 for DLBCL) | 66 (21–87) | Phase II | 3 | 35 (28 for DLBCL) | 13 (7 for DLBCL) | - |
aSubset of patients with aggressive NHL; bBased on total number of patients (N = 30); cNumber of patients in the pixantrone arm (total study N = 140); dBased on patients classified as ABC, unclassified, and unknown; eORR = 37% in a subset of patients with activated B-Cell DLBCL; fBased on patients classified as GCB; gNumber of patients in the lenalidomide arm (total study N = 102).
Abbreviations: ABC, activated B cell-like; CR, complete response; CRR, complete response rate; DLBCL, diffuse large B-cell lymphoma; DRR, durable response rate; GCB, germinal center B cell-like; NR, not reported; ORR, overall response rate.